Shots:
- Pfizer has reported the P-III (MagnetisMM-5) trial data assessing Elrexfio monotx. (SC) vs daratumumab + pomalidomide & dexamethasone for the treatment of adults (n= 497) with r/r MM who received prior ≥1L of treatment
- Trial met its 1EP of improved PFS, as assessed by BICR, while OS data (2EP) remain immature & is under assessment; data to be shared with regulators & submitted for presentation in future
- MagnetisMM trial program will continue to evaluate Elrexfio both as a monotx. & as a combination regimen, incl. fully recruited P-III (MagnetisMM-32) study in pts who have previously received daratumumab as part of SoC 1L MM treatment
Ref: Pfizer | Image: Pfizer | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
